We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.04 | -0.15% | 27.14 | 111,103 | 12:46:54 |
1. Name and Address of Reporting Person * LANKLER DOUGLAS M | 2. Issuer Name and Ticker or Trading Symbol PFIZER INC [ PFE ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Executive Vice President |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 2/25/2021 | M | 99816.0000 (1) | A | $22.8900 | 178092.0000 | D | |||
Common Stock | 2/25/2021 | F | 17246.0000 (2) | D | $33.8200 | 160846.0000 | D | |||
Common Stock | 2/25/2021 | F | 64599.0000 (3) | D | $34.7600 (4) | 96247.0000 | D | |||
Common Stock | 1626.0000 | I | By Rule 16b-3 Plan |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Appreciation Rights | $22.8900 | 2/25/2021 | M | 99816.0000 | 2/25/2021 | 2/25/2021 | Common Stock | 99816.0000 | $0.0000 | 0.0000 | D | ||||
Stock Appreciation Rights | $33.8200 | 2/25/2021 | A | 122907.0000 | 2/25/2026 (5) | 2/25/2026 (5) | Common Stock | 122907.0000 | $0.0000 | 122907.0000 | D | ||||
Stock Appreciation Rights | $33.8200 | 2/25/2021 | A | 106195.0000 | 2/25/2028 (6) | 2/25/2028 (6) | Common Stock | 106195.0000 | $0.0000 | 106195.0000 | D |
Remarks: In connection with the completed spinoff and combination of the Upjohn business with Mylan to create Viatris, and in accordance with their terms, adjustments were made to stock units, by providing additional Pfizer total shareholder return units (Stock Appreciation Rights) to plan participants in lieu of the Viatris dividend provided to shareholders, in order to maintain the same value post-transaction as the value of the outstanding awards prior to the transaction (subject to rounding). |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
LANKLER DOUGLAS M PFIZER INC.-CORP. SECRETARY 235 EAST 42ND ST. NEW YORK, NY 10017 | Executive Vice President |
Signatures | ||
Susan E. Grant, by power of atty., for Douglas M. Lankler | 3/1/2021 | |
**Signature of Reporting Person | Date |
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions